MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation.

@article{Giles2007MK0457AN,
  title={MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation.},
  author={Francis J Giles and Jorge E Cortes and Dan Jones and Donald A. Bergstrom and Hagop A Kantarjian and Steven J. Freedman},
  journal={Blood},
  year={2007},
  volume={109 2},
  pages={500-2}
}
MK-0457 (VX-680) is a small-molecule aurora kinase (AK) inhibitor with preclinical antileukemia activity. The T315I BCR-ABL mutation mediates resistance to imatinib, nilotinib, and dasatinib. MK-0457 has in vitro activity against cells expressing wild-type or mutated BCR-ABL, including the T315I BCR-ABL mutation. Three patients with T315I abl-mutated chronic myeloid leukemia (CML) or Philadelphia chromosome (Ph)-positive acute lymphocytic leukemia (ALL) have achieved clinical responses to doses… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 1 time. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 176 extracted citations

JAK2 inhibition for the treatment of hematologic and solid malignancies.

Expert opinion on investigational drugs • 2012
View 11 Excerpts
Highly Influenced

References

Publications referenced by this paper.
Showing 1-10 of 11 references

Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases.

Proceedings of the National Academy of Sciences of the United States of America • 2005

Similar Papers

Loading similar papers…